Recruiting

Phase 1

Phase 2

SPK-8011QQA Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Sponsor:

Hoffmann-La Roche

Code:

NCT07226206

Conditions

Hemophilia A

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SPK-8011QQ

Study Details

Brief summary:

This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.

Conditions

Hemophilia A

Study ID

NCT07226206

Start date

Sep 1, 2026

Status verified date

Aug, 2026

Completion date

Jul 31, 2031

Anticipated

Primary completion date

Jul 31, 2031

Anticipated

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Signed Informed Consent Form (ICF)
≥18 years of age at the time of signing the ICF
Male sex assigned at birth
Severe or moderately severe hemophilia A, defined as endogenous FVIII:C activity levels ≤3%, as documented (historically or during the Screening Period) by a certified laboratory and where the FVIII:C level is measured more than 96 hours after the prior dose of an extended half-life FVIII replacement product or more than 72 hours after the prior dose of a standard half-life FVIII replacement product
Have documented treatment for a minimum of 6 months prior to screening with either of the following: plasma coagulation factor VIII (FVIII) prophylaxis, defined as receiving a prescribed dose and frequency of FVIII infusions with the intent to treat continuously for 52 weeks per year; or FVIII on demand, with a history of ≥ 5 breakthrough bleeds in the 6 months prior to screening
No prior history of hypersensitivity or anaphylaxis associated with the administration of any FVIII product
Have ≥150 exposure days to a FVIII protein product such as recombinant, plasma-derived, or extended half-life FVIII product
Negative screening test for inhibitor against FVIII (i.e., <0.6 BU)
Candidates with prior FVIII inhibitors who are tolerized having completed successful ITI at least 5 years before screening are eligible provided they have had no evidence of inhibitor recurrence (permanent or temporary) within 5 years prior to screening as may be indicated by detection of an inhibitor, FVIII half-life <6 hours, or FVIII recovery <66% since completing ITI
Confirmed negative anti-Spark200 antibodies as documented through central laboratory testing of a serum sample
Acceptable hepatobiliary function according to all of the following criteria: ALT, AST, and ALP ≤2×ULN and INR <1.4 at the time of screening; No evidence of cirrhosis or advanced liver disease on screening liver ultrasound; Otherwise no laboratory or clinical evidence of liver disease or cirrhosis, per the Investigator's judgement
Adequate renal function, defined as creatinine clearance ≥30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration formula; patients on dialysis are not eligible for the study
Platelet count ≥50,0000 cells/µL
Negative HIV test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on an antiretroviral treatment regimen, have a cluster of differentiation (CD4) count >200/mm3, and undetectable viral load (<50 gc/mL)
Negative hepatitis B surface antigen (HBsAg) at screening
Positive hepatitis surface antibody (HBsAb) at screening, or a negative HBsAb at screening accompanied by either of the following: Negative hepatitis B core antibody (HBcAb); Positive HBcAb and negative hepatitis B virus (HBV) DNA test
Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test at screening accompanied by negative HCV RNA test
Otherwise appropriate medical history and physical and laboratory evaluation that are acceptable for inclusion in this clinical trial
Are able and willing to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including the completion of applicable patient-reported outcome questionnaires
Agreement to adhere to the contraception requirements described in the protocol

Exclusion Criteria:

Are currently undergoing antiviral therapy for chronic hepatitis B or chronic hepatitis C
Have an inherited or acquired bleeding disorder other than hemophilia A
Have known inherited or acquired thrombophilia, have signs of thromboembolic disease in the Investigator's judgement, or are on current treatment for thromboembolic disease. A history of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing is not considered an exclusion criterion
Have had prior treatment with a vector or gene transfer agent. Nucleic acid-based vaccines, such as the vaccine for coronavirus disease 2019 (COVID-19), are not considered gene transfer agents
Are receiving an investigational drug concurrently or have received an investigational drug within 30 days or 5 half-lives of the last investigational drug administration, whichever is longer
Have a major surgical procedure planned in the 15-month period following SPK-8011QQ infusion
Are unable (or unwilling) to receive blood or blood products (or any standard-of-care treatment for a life-threatening condition)
Have concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study or that would, in the opinion of the Investigator preclude the candidate's safe participation in and completion of the study, or the interpretation of the study results
History of malignancy within 5 years prior to screening and up to investigational study drug administration (Day 1) with the following exceptions: Participants with curatively treated basal or squamous cell carcinoma of the skin at any time prior to investigational study drug administration (Day 1) are eligible

Study Design

Enrollment

5 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: SPK-8011QQ

Participants will receive an intravenous (IV) infusion of SPK-8011QQ on Day 1 of the study.

Interventions

SPK-8011QQ

Participants will receive IV SPK-8011QQ

Primary outcome measure

Incidence of participants with adverse events (AEs) [ Time Frame: Up to approximately 5 years ]
Severity of AEs as determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 grading scale [ Time Frame: Up to approximately 5 years ]
Incidence of adverse events of special interest (AESIs) [ Time Frame: Up to approximately 5 years ]
Incidence of serious adverse events (SAEs) [ Time Frame: Up to approximately 5 years ]
Incidence of treatment-related AEs [ Time Frame: Up to approximately 5 years ]
Number of participants with abnormal laboratory values [ Time Frame: Up to approximately 5 years ]

Central Contacts and Locations

Central contacts

Reference Study ID Number: XO46084 https://forpatients.roche.com/ No email attachments.

888-662-6728 (U.S. and Canada)global-roche-genentech-trials@gene.com

Locations

Center for Inherited Blood Disorders

Recruiting

Orange, California, United States, 92868-4748

University of California San Francisco

Recruiting

San Francisco, California, United States, 94143-1222

Kaiser Permanente

Recruiting

Vallejo, California, United States, 94589-2441

More Information

Sponsor

Hoffmann-La Roche

Last update posted

Aug 4, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-08-04.